Marcella Fassò

TL;DR: Single-agent atezolizumab was well tolerated and provided durable clinical benefit in patients with mTNBC with stable or responding disease and in earlier lines of treatment.

TL;DR: Atezolizumab demonstrated a manageable safety profile and promising antitumor activity in patients with metastatic RCC and identified potential predictive and pharmacodynamic biomarkers that have guided ongoing studies and combinations with atezolIZumab in RCC.

TL;DR: MPDL3280A was generally well tolerated and demonstrated promising efficacy in pretreated metastatic PD-L1 IHC 2 or 3 TNBC pts, and circulating biomarker analyses revealed pharmacodynamic responses to MPDL32 80A.

TL;DR: Atezolizumab (atezo) is a humanized mAb that inhibits the binding of PD-L1 to PD-1 and B7, thus restoring tumor-specific T-cell immunity in triple negative breast cancer patients, and was generally well tolerated.

TL;DR: The preliminary findings suggest that biomarkers, including peripheral CD4+ T cells and hypermutated tumor status, may help guide selection of patients with recurrent glioblastoma who might receive most benefit from atezolizumab therapy, supporting further atzolizUMab combination studies in gliOBlastoma.